ClinicalTrials.gg

Leukemia, Myelomonocytic, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 540 studies for Leukemia, Myelomonocytic, Chronic across more than 10 countries. 69 are recruiting or about to start. 85 of them are mainly about Leukemia, Myelomonocytic, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 624 studies for Leukemia, Myelomonocytic, Chronic. How that becomes 540 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Leukemia, Myelomonocytic, Chronic, and those it files under no condition that list Leukemia, Myelomonocytic, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 624Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −9List Leukemia, Myelomonocytic, Chronic as a condition, but the registry did not file them under itMost often written as “Chronic Myelomonocytic Leukemia-2” (4), “Chronic Myelomonocytic Leukemia in Remission” (1), and “Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia” (1). The registry filed them under other conditions only, most often Myelodysplastic Syndromes (6) and Leukemia, Myeloid, Acute (5).
  3. −75Match it another way13 name it in the title, 3 in a keyword, and 59 by a synonym or other text the search reads.
  4. 540The count on this page

Status

Completed
316
Terminated
79
Recruiting
63
Active, not recruiting
36
Withdrawn
22
Status unknown
15

Phase

Phase 2
264
Phase 1
232
Phase 3
45
Early Phase 1
4

Where

United States
441
France
46
Germany
40
Canada
33
Italy
31
Spain
28

Who develops what

Add Leukemia, Myelomonocytic, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
venetoclaxRecent, repeated
Evidence
  • NCT06563804 · Servier Bio-Innovation LLC · Phase 2 · background · “Venetoclax” · registered Aug 2024
  • NCT05428969 · Faron Pharmaceuticals Ltd · Phase 2 · live · background · “Venetoclax” · registered Jun 2022
  • NCT05201066 · Novartis · Phase 2 · live · background · “venetoclax” · registered Jan 2022
  • NCT04581512 · Ellipses Pharma · Phase 2 · live · background · “Venetoclax” · registered Sep 2020
  • NCT04256317 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Venetoclax” · registered Jan 2020
AbbVie64% of its industry studiesUS: AbbVie (FDA 2016)EU: AbbVie (EMA 2016)33 studies
AzacitidineRecent, repeated
Evidence
  • NCT05428969 · Faron Pharmaceuticals Ltd · Phase 2 · live · background · “Azacitidine” · registered Jun 2022
  • NCT05201066 · Novartis · Phase 2 · live · background · “azacitidine” · registered Jan 2022
  • NCT04730258 · Treadwell Therapeutics, Inc · Phase 2 · live · background · “Azacitidine” · registered Jan 2021
  • NCT04581512 · Ellipses Pharma · Phase 2 · live · background · “Azacitidine (AZA)” · registered Sep 2020
  • NCT04358393 · Ascentage Pharma Group International · Phase 2 · live · background · “5-azacitidine” · registered Apr 2020
Bristol-Myers Squibb29% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 4 generics authorized22 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Nov 2027 est.S241656 · Servier · Phase 2 named, not the main aimstudied with posaconazoleNCT07719348 A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies — primary endpoint: (Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment · 64 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leukemia, Myelomonocytic, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 16 open · Tyrosine kinase inhibitors (TKIs) 12 open · Alkylating agents 10 open · JAK inhibitors 6 open · Calcineurin inhibitors 5 open

Coming up

39studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 63 Leukemia, Myelomonocytic, Chronic studies recruiting now, 47 (75%) set no upper age limit and 7 (11%) stop at 75 or younger. 8 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (6%) take healthy volunteers.

Recruiting studies that take each age, of 63
AgeWomenMen
103 (5%)3 (5%)
1862 (98%)62 (98%)
3062 (98%)62 (98%)
4062 (98%)62 (98%)
5062 (98%)62 (98%)
6562 (98%)62 (98%)
7559 (94%)59 (94%)
8550 (79%)50 (79%)

Across all 540 studies, recruiting or not: 23% stop at 75 or younger and 14% at 65; 28% take children; 0% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myelomonocytic, Chronic studies take

Of 69 phase 2 interventional studies under Leukemia, Myelomonocytic, Chronic, half reached primary completion within 68 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 151 mo31–74 · 66 studies—51 mo35–90 · 43 studies
Phase 1/2106 mo64–112 · 36 studies——
Phase 268 mo46–110 · 69 studies—70 mo46–111 · 62 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 540. Browse all 540 → or search them.